Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aficamten's Promise | Explore Cytokinetics' lead candidate aficamten, a potential game-changer in treating hypertrophic cardiomyopathy, with promising clinical trial results and market potential. |
Regulatory Milestones | Learn about Cytokinetics' progress in advancing aficamten through regulatory processes, including FDA acceptance and global approval reviews in Europe and China. |
Market Dynamics | Delve into aficamten's market positioning, competitive advantages, and potential to become a first-line therapy in the HCM treatment landscape. |
Financial Outlook | Analyst price targets for Cytokinetics range from $53 to $120, reflecting the potential upside of aficamten balanced against development and regulatory risks. |
Metrics to compare | CYTK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYTKPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.5x | −1.2x | −0.6x | |
PEG Ratio | −1.69 | −0.05 | 0.00 | |
Price/Book | −12.3x | 1.7x | 2.6x | |
Price / LTM Sales | 52.8x | 8.4x | 3.3x | |
Upside (Analyst Target) | 83.3% | 278.7% | 38.7% | |
Fair Value Upside | Unlock | 28.0% | 5.1% | Unlock |